A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation
Study Details
Study Description
Brief Summary
This study will evaluate the efficacy, safety and pharmacokinetics of RC48-ADC for injection combined with pyrotinib in subjects with local advanced or metastatic non-small cell lung cancer with HER2 mutation.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1/Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: RC48-ADC + Pyrotinib
|
Drug: RC48-ADC
RC48-ADC 1.5/2.0 mg/kg by intravenous (IV) infusion, given on Day 1 of each 14-day cycle
Other Names:
Drug: Pyrotinib
Pyrotinib 400 mg by oral once a day.
|
Outcome Measures
Primary Outcome Measures
- maximal tolerance dose (MTD) of RC48-ADC combined with Pyrotinib [DLT will be evaluated on 28 days of observation period]
Maximum-tolerated dose (MTD) was defined as the highest dose level at which no more than one of six patients experienced DLT during the DLT assessment window.
Secondary Outcome Measures
- Overall response rate (ORR) [Up to approximately 3 years]
The objective response rate will be mainly analyzed by investigators according to the RECIST 1.1 standard tumor evaluation.
- Disease control rate (DCR) [Up to approximately 3 years]
Disease control rate (DCR) is defined as cases where objective remission (assessed as complete remission or partial remission according to RECIST 1.1 standard) or stable disease during the study.
- Duration of relief (DOR) [Up to approximately 3 years]
DOR is defined as the time from the first documented objective response (CR or PR) to the first documented disease progression or death.
- Progression-free survival (PFS) [Up to approximately 3 years]
Progression-free survival (PFS) refers to the time from the date of randomization to the first researcher's evaluation of disease progression or death.
- Overall survival (OS) [Up to approximately 3 years]
The objective response rate will be mainly analyzed by investigators according to the RECIST 1.1 standard tumor evaluation
Eligibility Criteria
Criteria
Inclusion Criteria:
Voluntary agreement to provide written informed consent. Predicted survival ≥ 12 weeks. According to UICC/AJCC 8th Edition, histologically and/or cytologically-confirmed, cannot be surgically removed, locally advanced or metastatic NSCLC.
Is willing and able to provide an adequate archival tumor tissue sample Has relapsed from or is refractory to standard treatment and had received both platinum-based therapy and immunotherapy.
Measurable lesion according to RECIST 1.1. Documented HER2 exon 20 insertion mutation. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. Adequate organ function. For female subjects: should be surgically sterilized, postmenopausal, or agree to use a medically approved contraceptive (such as an intrauterine device, contraceptives, or condoms) during study treatment and within 6 months after the end of study, the blood pregnancy test within 7 days of study enrollment must be negative and must be non-lactating. Male subjects: Patients who should be surgically sterilized or agree to use a medically approved contraceptive during the study treatment period and within 6 months after the end of the study.
Willing and able to follow trial and follow-up procedures.
Exclusion Criteria:
No known EGFR, ALK, ROS1, RET, NTRK, MET 14 or BRAF V600E mutation. Patient has had previous treatment with HER2-targeted therapy prior to study participation.
History of major surgery within 4 weeks of planned start of trial treatment. Diagnosed with HBsAg, HBcAb positive and HBV DNA copy positive, or HCVAb positive, or HIVAb positive.
Has received a live virus vaccine within 4 weeks of planned start of trial treatment.
NYHA Class III heart failure. Suffering from active infection requiring systemic treatment. Uncontrolled hypertension, diabetes, Interstitial lung Disease, or COPD. Treated with systemic treatment (e.g. immunomodulators, corticosteroids or immunosuppressants) for the autoimmune disease within 2 years prior to the study treatment.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Shanghai Pulmonary Hospital | Shanghai | Shanghai | China | 200433 |
Sponsors and Collaborators
- RemeGen Co., Ltd.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- RC48-C021